Emerald Acquisition Ltd. purchased a new position in Pfizer Inc. (NYSE:PFE) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 15,770,357 shares of the biopharmaceutical company’s stock, valued at approximately $555,074,000. Pfizer makes up 1.0% of Emerald Acquisition Ltd.’s investment portfolio, making the stock its 5th largest position. Emerald Acquisition Ltd. owned approximately 0.26% of Pfizer as of its most recent SEC filing.
Other hedge funds have also modified their holdings of the company. Signature Financial Management Inc. raised its stake in shares of Pfizer by 5.3% in the second quarter. Signature Financial Management Inc. now owns 25,950 shares of the biopharmaceutical company’s stock worth $915,000 after buying an additional 1,314 shares during the period. Kleinwort Benson Investors Dublin Ltd acquired a new stake in shares of Pfizer during the second quarter worth approximately $71,436,000. New Mexico Educational Retirement Board raised its stake in shares of Pfizer by 3.4% in the second quarter. New Mexico Educational Retirement Board now owns 706,750 shares of the biopharmaceutical company’s stock worth $24,885,000 after buying an additional 23,400 shares during the period. AMG National Trust Bank acquired a new stake in shares of Pfizer during the second quarter worth approximately $240,000. Finally, Front Barnett Associates LLC raised its stake in shares of Pfizer by 5.3% in the second quarter. Front Barnett Associates LLC now owns 14,024 shares of the biopharmaceutical company’s stock worth $494,000 after buying an additional 700 shares during the period. Institutional investors and hedge funds own 69.65% of the company’s stock.
Shares of Pfizer Inc. (NYSE:PFE) traded up 1.65% on Friday, reaching $33.87. The company had a trading volume of 28,593,974 shares. The stock’s 50 day moving average is $34.48 and its 200 day moving average is $34.04. Pfizer Inc. has a 52 week low of $28.25 and a 52 week high of $37.39. The firm has a market capitalization of $205.44 billion, a price-to-earnings ratio of 30.03 and a beta of 0.87.
Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, August 2nd. The biopharmaceutical company reported $0.64 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.62 by $0.02. The firm earned $13.10 billion during the quarter, compared to analyst estimates of $13.01 billion. Pfizer had a return on equity of 23.37% and a net margin of 14.88%. The business’s quarterly revenue was up 10.9% compared to the same quarter last year. During the same quarter last year, the business posted $0.56 earnings per share. On average, equities analysts anticipate that Pfizer Inc. will post $2.46 EPS for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 1st. Stockholders of record on Friday, November 11th will be given a dividend of $0.30 per share. The ex-dividend date of this dividend is Tuesday, November 8th. This represents a $1.20 dividend on an annualized basis and a dividend yield of 3.54%. Pfizer’s payout ratio is 95.24%.
A number of analysts recently commented on the company. Bank of America Corp. reiterated a “buy” rating and set a $40.00 price target on shares of Pfizer in a report on Tuesday. Sanford C. Bernstein reiterated an “outperform” rating on shares of Pfizer in a report on Monday, September 26th. Jefferies Group dropped their price target on Pfizer from $40.00 to $39.00 and set a “buy” rating on the stock in a report on Tuesday, September 13th. Argus reiterated a “buy” rating and set a $39.00 price target on shares of Pfizer in a report on Sunday, August 28th. Finally, Piper Jaffray Cos. set a $54.00 target price on Pfizer and gave the stock a “buy” rating in a research report on Tuesday, August 23rd. Ten investment analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $38.78.
Pfizer Company Profile
Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.